PRNewsWire
25 Jun 2026, 11:45 UTC · 13w ago
Verdict
Headline takes no side. We score VBIO +1.00 across four claims — strongly bullish.
+1.00strongly bullish
More positive than 99% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
AFRRI and NIAID have finalized a survival efficacy protocol to evaluate Valion Bio's lead candidate, Entolimod, for the treatment of Gastrointestinal Acute Radiation Syndrome (GI-ARS).
More positive than 94% of claims this week
Entolimod is being positioned as a potential first-and-only treatment for GI-ARS, a condition with no currently FDA-approved medical countermeasures.
So whatEstablishing a first-mover advantage in a market with a total unmet need creates significant commercial upside and pricing power.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 87% of claims this week
The protocol utilizes the PBI-BM2.5 murine model, which meets FDA Animal Rule criteria for drug approval when human trials are unethical.
More positive than 80% of claims this week
The broader Acute Radiation Syndrome (ARS) medical countermeasures market is projected to reach $7.80 billion by 2032.
More positive than 55% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company reached a key inflection point with the finalization of a survival efficacy protocol for its lead candidate Entolimod, targeting a multi-billion-dollar market.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Business Wire
3h ago
−76.6%
Price is moving against the score
$3.17 vs $13.50 close before publication (Jun 24) · not market-adjusted
VBIO chart →
